A Novel Cell-Penetrating Antibody Fragment Inhibits the DNA Repair Protein RAD51

Landon Pastushok, Yongpeng Fu, Leo S. Lin, Yu Luo, John F. DeCoteau, Ken Lee, C. Ronald Geyer

Scientific Reports · 2019 · 21 citations · 70 references

DOIFull text

Open access

Concepts

Abstract

Abstract DNA damaging chemotherapies are successful in cancer therapy, however, the damage can be reversed by DNA repair mechanisms that may be up-regulated in cancer cells. We hypothesized that inhibiting RAD51, a protein involved in homologous recombination DNA repair, would block DNA repair and restore the effectiveness of DNA damaging chemotherapy. We used phage-display to generate a novel synthetic antibody fragment that bound human RAD51 with high affinity (K D = 8.1 nM) and inhibited RAD51 ssDNA binding in vitro . As RAD51 is an intracellular target, we created a corresponding intrabody fragment that caused a strong growth inhibitory phenotype on human cells in culture. We then used a novel cell-penetrating peptide “iPTD” fusion to generate a therapeutically relevant antibody fragment that effectively entered living cells and enhanced the cell-killing effect of a DNA alkylating agent. The iPTD may be similarly useful as a cell-penetrating peptide for other antibody fragments and open the door to numerous intracellular targets previously off-limits in living cells.

References

70